The closing price of Irobot Corp (NASDAQ: IRBT) was $7.85 for the day, down -13.59% from the previous closing price of $9.09. On the day, 2850219 shares were traded.
Ratios:
Our analysis of IRBT’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.09 and its Current Ratio is at 1.62. In the meantime, Its Debt-to-Equity ratio is 1.19 whereas as Long-Term Debt/Eq ratio is at 1.17.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on May 06, 2022, Downgraded its rating to Underweight and sets its target price to $45 from $65 previously.
On March 24, 2022, Northland Capital Upgraded its rating to Outperform which previously was Market Perform but kept the price unchanged to $85.
JP Morgan Downgraded its Overweight to Neutral on July 29, 2021, while the target price for the stock was maintained at $103.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 29 ’24 when Angle Colin M sold 179,503 shares for $11.46 per share. The transaction valued at 2,057,356 led to the insider holds 14,797 shares of the business.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 0.26 while its Price-to-Book (P/B) ratio in mrq is 1.12.
Stock Price History:
Over the past 52 weeks, IRBT has reached a high of $51.49, while it has fallen to a 52-week low of $7.62.
Shares Statistics:
A total of 27.96M shares are outstanding, with a floating share count of 27.53M. Insiders hold about 3.22% of the company’s shares, while institutions hold 76.62% stake in the company.
Earnings Estimates
The firm’s stock currently is rated by IO Biotech, Inc. analysts. The consensus estimate for the next quarter is $7.85, with high estimates of $16.00 and low estimates of $0.35.
Analysts are recommending an EPS of between $Real Estate and $Technology for the fiscal current year, implying an average EPS of $Consumer Cyclical.
